Buy These 2 Stocks Before They Jump Over 100%, Says Oppenheimer



Cassava Stock Could Jump More Than 200 Times

Given the potential, tremendous benefits of Cassava’s Alzheimer’s drug for millions of patients and the high probability of the drug being approved, I believe that Cassava Sciences (NASDAQ:SAVA) stock is vastly undervalued. Source: Pavel Kapysh / Additionally, my calculations indicate that the shares could easily soar over 200x after the company’s Alzheimer’s treatment, simufilam, is approved by the FDA. Meanwhile, there’s evidence that strong support for the drug is building am

: ByteDance founder Zhang Yiming steps down as chairman: reports

Previous article

Atlanta Braves beat Houston Astros to win their first World Series since 1995

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News